Changes in spike protein antibody titer over 90 days after the second dose of SARS-CoV-2 vaccine in Japanese dialysis patients

[1]  N. Ohmagari,et al.  Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave , 2022, International Journal of Infectious Diseases.

[2]  N. Bar-Zeev,et al.  Post-Vaccination Neutralization Responses to Omicron Sub-Variants , 2022, medRxiv.

[3]  J. Doudna,et al.  Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[5]  K. Bruxvoort,et al.  Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants , 2022, Nature Medicine.

[6]  D. Miskulin,et al.  SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patients , 2021, medRxiv.

[7]  D. Weiner,et al.  Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months , 2021, medRxiv.

[8]  D. Chartoumpekis,et al.  Sars-Cov-2 antibody titer 3 months post-vaccination is affected by age, gender, smoking and vitamin D. , 2021, medRxiv.

[9]  J. Izopet,et al.  Antibody titers and protection against a SARS-CoV-2 infection , 2021, Journal of Infection.

[10]  V. Caudwell,et al.  SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis , 2021, American Journal of Kidney Diseases.

[11]  A. Schäffer,et al.  Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection , 2021, medRxiv.

[12]  C. Tomomori-Sato,et al.  Comparison of Antibody Levels in Response to SARS-CoV-2 Infection and Vaccination Type in a Midwestern Cohort , 2021, medRxiv.

[13]  K. Sugiyama,et al.  Age and Smoking Predict Antibody Titres at 3 Months after the Second Dose of the BNT162b2 COVID-19 Vaccine , 2021, medRxiv.

[14]  A. Dębska-Ślizień,et al.  Humoral response to SARS-CoV-2 vaccination promises to improve the catastrophic prognosis of hemodialysis patients as a result of COVID-19. The COViNEPH Project. , 2021, Polish archives of internal medicine.

[15]  M. Abu-Farha,et al.  Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination , 2021, Frontiers in Immunology.

[16]  M. Pacenti,et al.  COVID-19 convalescent plasma donors: impact of vaccination on antibody levels, breakthrough infections and reinfection rate. , 2021, medRxiv.

[17]  D. Teupser,et al.  Antibody response to mRNA SARS-CoV-2 vaccines in haemodialysis patients , 2021, Clinical kidney journal.

[18]  J. Achard,et al.  Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients , 2021, Journal of the American Society of Nephrology : JASN.

[19]  D. Segev,et al.  Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series , 2021, Annals of Internal Medicine.

[20]  S. Ohtori,et al.  Antibody responses to BNT162b2 mRNA COVID-19 vaccine in 2,015 healthcare workers in a single tertiary referral hospital in Japan , 2021, medRxiv.

[21]  S. Boyd,et al.  Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis , 2021, medRxiv.

[22]  G. Jakiel,et al.  Is WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin Clinically Useful? , 2021, medRxiv.

[23]  D. Weiner,et al.  Immunogenicity of SARS-CoV-2 Vaccine in Dialysis , 2021, medRxiv.

[24]  D. Schwartz,et al.  Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[25]  A. Kribben,et al.  Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis , 2021, Vaccines.

[26]  H. Schaal,et al.  Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination , 2021, medRxiv.

[27]  D. Schwartz,et al.  Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis , 2021 .

[28]  M. Tokumoto,et al.  Modified creatinine index and risk for long-term infection-related mortality in hemodialysis patients: ten-year outcomes of the Q-Cohort Study , 2020, Scientific Reports.

[29]  K. Nitta.  2019 Annual Dialysis Data Report, JSDT Renal Data Registry , 2020 .

[30]  H. Morgenstern,et al.  US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  I. Masakane.  2016 Annual Dialysis Data Report, JSDT Renal Data Registry , 2018 .

[32]  M. Periasamy,et al.  Skeletal Muscle Thermogenesis and Its Role in Whole Body Energy Metabolism , 2017, Diabetes & metabolism journal.

[33]  Douglas E Schaubel,et al.  US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  P. Kerr,et al.  Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices , 2016, The Lancet.

[35]  C. Handschin,et al.  Skeletal muscle as an endocrine organ: PGC-1α, myokines and exercise. , 2015, Bone.

[36]  N. Molinari,et al.  Creatinine Index as a Surrogate of Lean Body Mass Derived from Urea Kt/V, Pre-Dialysis Serum Levels and Anthropometric Characteristics of Haemodialysis Patients , 2014, PloS one.

[37]  F. Port,et al.  Dialysis Outcomes and Practice Patterns Study (DOPPS): its strengths, limitations, and role in informing practices and policies. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[38]  I. Narita,et al.  High Mortality Rate of Infectious Diseases in Dialysis Patients: A Comparison With the General Population in Japan , 2012, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[39]  Takashi Akiba,et al.  Vascular access use and outcomes: an international perspective from the dialysis outcomes and practice patterns study , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[40]  M. Ragaller,et al.  [Therapy of hyperthermia in sepsis and septic shock. Necessary or injurious?]. , 2007, Der Anaesthesist.

[41]  Francesco Locatelli,et al.  Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[42]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[43]  B. Jaber,et al.  Pulmonary infectious mortality among patients with end-stage renal disease. , 2001, Chest.

[44]  B. Jaber,et al.  Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. , 2000, Kidney international.